BioLineRx Ltd. (BLRX)

Market Cap	11.87M -35.3%
Revenue (ttm)	1.39M -91.9%
Net Income	-6.99M
EPS	-0.00
Shares Out	2.62B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,887
Open	2.220
Previous Close	2.216
Day's Range	2.220 - 2.249
52-Week Range	2.150 - 4.500
Beta	0.70
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 23, 2026

About BLRX

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2011
• Employees: 24
• Stock Exchange: Nasdaq
• Ticker Symbol: BLRX
• Website: https://www.biolinerx.com

Financial Performance

In 2025, BioLineRx's revenue was $1.18 million, a decrease of -95.92% compared to the previous year's $28.94 million. Losses were -$1.18 million, -87.26% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 12, 2026

Data Sources Report a data error